Kåre Engkilde is working as an Entrepreneur in Residence at BioInnovation Institute for the SpaceM project, alongside being a consultant for several life science companies covering Diagnostics, MedTech, and Therapeutics across Europe.
He previously worked as a CEO for the Swedish biotech company Amniotic, which focused on developing stem cell therapies for respiratory, renal, neuronal, and oncology disorders. During this time, he scaled the company, raised capital, and got it listed on the stock exchange while initiating collaborations with pharma and biotech companies in Europe and APAC.
He scaled the company, raised capital, listed it on the stock exchange, and initiated collaborations with pharma and biotech companies in Europe and APAC. Before that, Kåre has worked for several companies, big and small, across the life science arena in R&D, Clinical, and Commercial roles. He has an educational background in biochemical engineering complemented by a PhD in dermatology, immunology, and epidemiology.